On April 28, 2017, the US Food and Drug Administration approved midostaurin (Rydapt) for treating newly diagnosed FLT3-mutated acute myeloid leukemia and three types of systemic mastocytosis.
Peripheral blood analysis may provide valuable insights into non–small-cell lung cancer patients’ responses to PD-1-targeted therapies.
A new study is suggesting that testing for variants in seven cancer-associated genes followed by risk-reduction management could cost-effectively improve life expectancy for women at risk for hereditary breast cancer.
Researchers in Seattle are now reporting success with a biopolymer synthetic scaffold loaded with cancer-fighting T cells and a mix of nutrients to potentially combat solid tumors.
Using state-of-the-art gene editing technology, researchers have discovered a promising target to treat atypical teratoid/rhabdoid tumor (AT/RT), a highly aggressive and therapy-resistant brain tumor.
An analysis from Project Genomics Evidence Neoplasia Information Exchange (GENIE) was presented at the American Association for Cancer Research Annual Meeting.
An experimental compound known as G100 may be a potentially viable agent for local control of metastatic soft tissue sarcomas.
The FDA on March 30, 2017, granted full approval to osimertinib for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC.
Researchers at the Johns Hopkins University Bloomberg School of Public Health say they have found several gene variants which may predispose individuals to develop gall bladder cancer.
A new international study has identified 12 new genetic variants associated with an increased risk of developing epithelial ovarian cancer.